{
    "clinical_study": {
        "@rank": "138088", 
        "brief_summary": {
            "textblock": "RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver\n      tumor-killing substances to them without harming normal cells.\n\n      PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody and\n      cyclophosphamide in treating patients with metastatic cancer."
        }, 
        "brief_title": "Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer", 
        "condition": "Unspecified Adult Solid Tumor, Protocol Specific", 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Evaluate the clinical feasibility and toxicity of monoclonal antibody OKT3\n      given with low-dose cyclophosphamide in patients with advanced malignancies. II. Perform\n      serial immune monitoring on patients treated with this regimen. III. Identify any clinical\n      responses produced by this regimen.\n\n      OUTLINE: Biological Response Modifier Therapy with Suppressor Cell Inhibition. Anti-CD3\n      Murine Monoclonal Antibody OKT3, MOAB OKT3; with Cyclophosphamide, CTX, NSC-26271.\n\n      PROJECTED ACCRUAL: At least 9 evaluable patients per diagnostic category will be required\n      initially; if any response is seen during the dose-finding portion of the study, a total of\n      24 patients with that diagnosis will be entered."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Metastatic cancer considered incurable by standard therapy and\n        for which no higher priority protocol is available Locally progressive primary brain\n        tumors (e.g., astrocytoma, glioma) are also eligible Brain metastases allowed\n\n        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-4 (poor performance\n        status brain tumor patients specifically eligible) Life expectancy: At least 2 months\n        Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Pulmonary: No\n        history of adult asthma No emphysema No pulmonary insufficiency No pulmonary edema Other:\n        No AIDS or positive HIV serology No pregnant women\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified\n        Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002482", 
            "org_study_id": "CDR0000077247", 
            "secondary_id": [
                "SVMC-ONC-121", 
                "NCI-V90-0206"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "antibody therapy", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "biological therapy", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "muromonab-CD3", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Antibodies, Monoclonal", 
                "Cyclophosphamide", 
                "Muromonab-CD3"
            ]
        }, 
        "keyword": "unspecified adult solid tumor, protocol specific", 
        "lastchanged_date": "November 5, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/SVMC-ONC-121"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90057"
                }, 
                "name": "St. Vincent Medical Center - Los Angeles"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A PHASE I-II TRIAL OF MUROMONAB (OKT-3) WITH LOW-DOSE CYCLOPHOSPHAMIDE", 
        "overall_official": {
            "last_name": "Charles L. Wiseman, MD, FACP", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1/Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002482"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Vincent Medical Center - Los Angeles", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 1991", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2007"
    }, 
    "geocoordinates": {
        "St. Vincent Medical Center - Los Angeles": "34.052 -118.244"
    }
}